ORGAN-SPARING TREATMENT OF ADVANCED BLADDER-CANCER - A 10-YEAR EXPERIENCE

被引:138
|
作者
DUNST, J
SAUER, R
SCHROTT, KM
KUHN, R
WITTEKIND, C
ALTENDORFHOFMANN, A
机构
[1] UNIV ERLANGEN NURNBERG,DEPT RADIOTHERAPY,D-91054 ERLANGEN,GERMANY
[2] UNIV ERLANGEN NURNBERG,DEPT UROL,W-8520 ERLANGEN,GERMANY
[3] UNIV ERLANGEN NURNBERG,DEPT PATHOL,W-8520 ERLANGEN,GERMANY
[4] UNIV ERLANGEN NURNBERG,CTR TUMOR,W-8520 ERLANGEN,GERMANY
关键词
BLADDER CANCER; RADIOTHERAPY; TRANSURETHRAL SURGERY; CHEMOTHERAPY; BLADDER PRESERVATION;
D O I
10.1016/0360-3016(94)90003-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Radical cystectomy is considered as standard therapy for muscle-invasive bladder cancer. We present 10-year results of bladder-sparing treatment by conservative surgery and radiotherapy +/- chemotherapy. Methods and Materials: From 1982 through 1991, 245 consecutive patients, mean age 66 years, with invasive bladder cancer (T2-3 or poor prognostic T1, no distant metastases) entered a prospective protocol with the objective of bladder preservation. Treatment consisted of transurethral resection (complete, if possible) and definitive radiotherapy with 56 Gy maximum dose (50.4 Gy minimum target dose) in 28 fractions. Since 1985, 139 patients received a simultaneous chemotherapy on 5 days in the first and fifth treatment week with either 25 mg/m(2) cisplatin daily (79 patients) or 65 mg/m(2) carboplatin (60 patients). Cystectomy was performed as salvage treatment for residual or recurrent invasive disease. The median follow-up at the date of analysis (12-31-92) was 5.9 years. Results: The overall survival was 47% after 5 years and 26% after 10 years. The 5-year survival according to the initial T-category was 60% for T1 (44 patients), 64% for T2 (47 patients), 43% for T3 (127 patients), and 16% for T4 (23 patients). The most important single prognostic factor was the amount of residual tumor after TUR (5-year survival 80% after R0, 53% after R1, and 31% after R2 resection, p < 0.01). Chemotherapy increased the rate of complete remission, but had no impact on 5-year survival (52% vs. 50%). Fifty-three salvage cystectomies were performed, all without severe complications, and 192 patients (79%) maintained a normal functioning bladder. The bladder preservation rate in 5-year survivors was 83%. Conclusions: Organ-sparing treatment of advanced bladder cancer by transurethral surgery and definitive radiotherapy or radiochemotherapy is feasible and effective. The survival in this series is as good as in any comparable cystectomy series. Eighty-three percent of long-term survivors maintained their functioning bladders.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 50 条
  • [41] Advantages of organ-sparing treatment approaches in metastatic kidney cancer
    Iurii Vitruk
    Oleg Voylenko
    Oleksandr Stakhovsky
    Oleksii Kononenko
    Maksym Pikul
    Sofiya Semko
    Bohdan Hrechko
    Denis Koshel
    Eduard Stakhovsky
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 3131 - 3137
  • [42] Organ-sparing procedures in GU cancer: part 3-organ-sparing procedures in urothelial cancer of upper tract, bladder and urethra
    Khalil, Mahmoud, I
    Alliston, Jeffrey T.
    Bauer-Erickson, Jonathan J.
    Davis, Rodney
    Bissada, Nabil K.
    Kamel, Mohamed H.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (11) : 1903 - 1911
  • [43] Organ-sparing surgical and nonsurgical modalities in primary penile cancer treatment
    Raskin, Yannic
    Vanthoor, Joren
    Milenkovic, Uros
    Muneer, Asif
    Albersen, Maarten
    CURRENT OPINION IN UROLOGY, 2019, 29 (02) : 156 - 164
  • [44] SURVIVAL OF PATIENTS WITH SUPERFICIAL BLADDER-CANCER AFTER TREATMENT - A 10-YEAR RETROSPECTIVE FOLLOW-UP-STUDY
    UCHIDA, K
    SHIMAZUI, T
    NEMOTO, R
    KANO, S
    KOISO, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1984, 14 (03) : 369 - 377
  • [45] The efficacy of organ-sparing therapies for penile cancer
    Nature Clinical Practice Urology, 2007, 4 (1): : 6 - 6
  • [46] Organ-sparing procedures in GU cancer: part 3-organ-sparing procedures in urothelial cancer of upper tract, bladder and urethra
    Mahmoud I. Khalil
    Jeffrey T. Alliston
    Jonathan J. Bauer-Erickson
    Rodney Davis
    Nabil K. Bissada
    Mohamed H. Kamel
    International Urology and Nephrology, 2019, 51 : 1903 - 1911
  • [47] Role of radiotherapy in organ-sparing treatment of seminoma
    Amanda Flaquer
    Ana Álvarez
    Silvia M. Sánchez
    Clinical and Translational Oncology, 2008, 10
  • [48] Patient preferences for surgical and organ-sparing treatment approaches for rectal cancer
    Couwenberg, A. M.
    Intven, M. P. W.
    Burbach, J. P. M.
    Emaus, M. J.
    Van Grevenstein, W. M. U.
    Verkooijen, H. M.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S411 - S412
  • [49] Organ-Sparing Treatment of Advanced Bladder CancerPaclitaxel as a RadiosensitizerOrganerhaltende Behandlung bei fortgeschrittenen Harnblasenkarzinomen. Paclitaxel als Radiosensitizer
    Arndt-Christian Müller
    Andrea Diestelhorst
    Thomas Kuhnt
    Reinhard Kühn
    Paolo Fornara
    Hans-Jörg Scholz
    Jürgen Dunst
    Anthony Laurence Zietman
    Strahlentherapie und Onkologie, 2007, 183 (4) : 177 - 183
  • [50] ORGAN-SPARING SURGERY IN BILATERAL TESTICULAR CANCER
    HEIDENREICH, A
    STARK, L
    DERSCHUM, W
    VONVIETSCH, H
    UROLOGE A, 1993, 32 (01): : 43 - 48